

The information contained within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014, as incorporated into UK law by the European Union (Withdrawal) Act 2018. Upon the publication of this announcement, this inside information is now considered to be in the public domain.

18 December 2024



CRISM Therapeutics Corporation
("CRISM", "CRISM Therapeutics" or the "Company")

European Patent Grant

CRISM Therapeutics Corporation (AIM: CRTX) the innovative UK drug delivery company focused on the localised delivery of chemotherapy drugs, is pleased to announce that it has been granted a European patent (EP4072552) by the European Patent Office.

The patent relates to the Company's lead product, ChemoSeed®, for chemotherapeutic drug implants and more, particularly, to biodegradable chemotherapeutic drug implants comprising irinotecan. ChemoSeed was invented by Professor Chris McConville, CRISM's Chief Scientific Officer.

The patent covers the manufacturing processes for the preparation of these chemotherapeutic drug implants and to their use in therapy, in particular in treating brain tumours such as high grade glioma. The Company believes that local delivery of irinotecan directly to the brain tumour resection site could improve therapeutic outcomes by allowing for the delivery of larger doses directly to the tumour site, while reducing systemic concentrations and thus alleviating the traditional side-effects.

The Company has patents submitted in other key jurisdictions and will update the market as to their progress accordingly.

Commenting on the patent grant, CRISM CEO Andrew Webb said: *The granting of this patent by the European patent office is a key milestone for CRISM and further validates the novelty of ChemoSeed. Additionally, this provides CRISM IP protection in one of our key markets whilst enhancing ChemoSeed's appeal to potential commercial partners. The Board believes that ChemoSeed could improve therapeutic outcomes for brain tumour patients and we look forward to demonstrating this as we prepare for a clinical trial in 2025.*

-Ends-

Enquiries:

Company	Nomad and Broker	Financial PR
CRISM Therapeutics Corporation	S.P. Angel Corporate Finance LLP	Burson Buchanan
Andrew Webb, CEO	Richard Morrison	Mark Court / Jamie Hooper
Chris McConville, CSO	Adam Cowl	CRISM@buchanancomms.co.uk
via Burson Buchanan	+44 (0) 20 3470 0470	+44 (0) 20 7466 5000

About CRISM Therapeutics Corporation

CRISM Therapeutics Corporation has developed an innovative drug delivery technology to improve the clinical performance of cancer treatments for solid tumours through the local delivery of chemotherapy drugs.

ChemoSeed, CRISM's lead product, can be implanted directly into the tumour or the resection margin following the removal of a tumour. This directs that therapeutic concentrations of chemotherapy drugs reach the deep-seated tumour tissue or cover the entire resection margin. In the case of treating high-grade glioma, ChemoSeeds can be implanted during surgery thereby bypassing the blood brain barrier, which prevents other treatments from being able to reach the tumour and be effective.

CRISM plans to submit a clinical trial application for ChemoSeed® in high-grade glioma Based on preclinical data, the Tessa Jowell BRAIN MATRIX Scientific Advisory Board has approved ChemoSeed in a phase II platform clinical trial which is an efficient and cost-effective clinical development opportunity.

For more information please visit: <https://www.crismltherapeutics.com/>

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@seg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

REAEAKAXFDELFFA